Cencora Inc.
Cencora, Inc. Reports Strong Q3 2024 Earnings and Raises Fiscal 2024 Guidance
Summary
On July 31, 2024, Cencora, Inc. announced its financial results for the third quarter of fiscal 2024, reporting a 10.9% year-over-year increase in revenue to $74.2 billion. The company's GAAP diluted EPS was $2.42, while adjusted diluted EPS was $3.34, up 14.4% from the prior year. Cencora also raised its adjusted diluted EPS guidance for fiscal 2024 to a range of $13.55 to $13.65. The company will host a conference call on July 31, 2024, to discuss these results and related matters.
Profitelligence Alerts
Get alerts for COR
Be first to know when Cencora Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cencora Inc.
Cencora Inc., formerly known as AmerisourceBergen Corporation, represents a pivotal entity in the global healthcare distribution and services sector. As a leading pharmaceutical sourcing and distribution services company, Cencora Inc. plays a critical role in ensuring the efficient supply of pharmaceutical products to a range of healthcare providers, including hospitals, pharmacies, and clinics. Its business model is centered on the seamless integration of logistics, consulting services, and the provision of innovative solutions aimed at improving pharmaceutical supply chain operations. Cencora Inc. impacts various segments of the healthcare industry by enhancing the availability and accessibility of healthcare products. Known for its global reach and extensive network of distribution centers, the company supports the delivery of critical medications and healthcare products across numerous geographies. Cencora Inc.'s significance in the market is underscored by its ability to partner with pharmaceutical manufacturers and healthcare providers to streamline processes, reduce costs, and improve patient outcomes. Headquartered in Conshohocken, Pennsylvania, Cencora Inc. remains a cornerstone of the healthcare distribution market, focusing on sustainability, innovation, and strategic collaborations.
Official SEC Documents
Advertisement